09 December 2021 : Database Analysis
Low Expression of Long Noncoding RNA SLC26A4 Antisense RNA 1 Is an Independent Prognostic Biomarker and Correlate of Immune Infiltrates in Breast Cancer
Weiwei Yi1ABCEF, Haiqing Shen2BC, Dexi Sun3BC, Yongchao Xu4BC, Yujie Feng1BC, Dongbing Li5BC, Caixia Wang1ABCEF*DOI: 10.12659/MSM.934522
Med Sci Monit 2021; 27:e934522
Table 2 Expression of SLC26A4-AS1 in breast cancer is associated with clinical characteristics.
| Characteristic | Low expression of SLC26A4-AS1 | High expression of SLC26A4-AS1 | p | Statistic | Method |
|---|---|---|---|---|---|
| n | 541 | 542 | |||
| T stage, n (%) | 0.909 | 0.54 | Chisq.test | ||
| T1 | 140 (13%) | 137 (12.7%) | |||
| T2 | 309 (28.6%) | 320 (29.6%) | |||
| T3 | 71 (6.6%) | 68 (6.3%) | |||
| T4 | 19 (1.8%) | 16 (1.5%) | |||
| N stage, n (%) | 0.536 | 2.18 | Chisq.test | ||
| N0 | 245 (23%) | 269 (25.3%) | |||
| N1 | 179 (16.8%) | 179 (16.8%) | |||
| N2 | 61 (5.7%) | 55 (5.2%) | |||
| N3 | 42 (3.9%) | 34 (3.2%) | |||
| M stage, n (%) | 0.836 | 0.04 | Chisq.test | ||
| M0 | 452 (49%) | 450 (48.8%) | |||
| M1 | 11 (1.2%) | 9 (1%) | |||
| Pathologic stage, n (%) | 0.736 | 1.27 | Chisq.test | ||
| Stage I | 87 (8.2%) | 94 (8.9%) | |||
| Stage II | 306 (28.9%) | 313 (29.5%) | |||
| Stage III | 123 (11.6%) | 119 (11.2%) | |||
| Stage IV | 11 (1%) | 7 (0.7%) | |||
| Race, n (%) | 0.945 | 0.11 | Chisq.test | ||
| Asian | 30 (3%) | 30 (3%) | |||
| Black or African American | 89 (9%) | 92 (9.3%) | |||
| White | 363 (36.5%) | 390 (39.2%) | |||
| Age, n (%) | <0.001 | 11.49 | Chisq.test | ||
| ≤60 | 272 (25.1%) | 329 (30.4%) | |||
| >60 | 269 (24.8%) | 213 (19.7%) | |||
| Histological type, n (%) | 0.940 | 0.01 | Chisq.test | ||
| Infiltrating ductal carcinoma | 387 (39.6%) | 385 (39.4%) | |||
| Infiltrating lobular carcinoma | 104 (10.6%) | 101 (10.3%) | |||
| PR status, n (%) | <0.001 | Fisher.test | |||
| Negative | 141 (13.6%) | 201 (19.4%) | |||
| Indeterminate | 2 (0.2%) | 2 (0.2%) | |||
| Positive | 375 (36.3%) | 313 (30.3%) | |||
| ER status, n (%) | <0.001 | Fisher.test | |||
| Negative | 89 (8.6%) | 151 (14.6%) | |||
| Indeterminate | 1 (0.1%) | 1 (0.1%) | |||
| Positive | 428 (41.4%) | 365 (35.3%) | |||
| HER2 status, n (%) | 0.624 | 0.94 | Chisq.test | ||
| Negative | 274 (37.7%) | 284 (39.1%) | |||
| Indeterminate | 5 (0.7%) | 7 (1%) | |||
| Positive | 71 (9.8%) | 86 (11.8%) | |||
| PAM50, n (%) | <0.001 | 82.17 | Chisq.test | ||
| Normal | 7 (0.6%) | 33 (3%) | |||
| LumA | 291 (26.9%) | 271 (25%) | |||
| LumB | 139 (12.8%) | 65 (6%) | |||
| Her2 | 48 (4.4%) | 34 (3.1%) | |||
| Basal | 56 (5.2%) | 139 (12.8%) | |||
| Menopause status, n (%) | 0.002 | 12.79 | Chisq.test | ||
| Pre | 91 (9.4%) | 138 (14.2%) | |||
| Peri | 17 (1.7%) | 23 (2.4%) | |||
| Post | 372 (38.3%) | 331 (34.1%) | |||
| Anatomic neoplasm subdivisions, n (%) | 0.236 | 1.4 | Chisq.test | ||
| Left | 271 (25%) | 292 (27%) | |||
| Right | 270 (24.9%) | 250 (23.1%) | |||
| Radiation therapy, n (%) | 0.576 | 0.31 | Chisq.test | ||
| No | 219 (22.2%) | 215 (21.8%) | |||
| Yes | 268 (27.2%) | 285 (28.9%) | |||
| Age, median (IQR) | 60 (51, 69) | 55 (47, 65) | <0.001 | 171329 | Wilcoxon |